You-Ren Ji,Yong Ju,Hui Kong et al. You-Ren Ji et al.

Together, these results establish CaReCa as a sensitive, specific, and scalable liquid biopsy platform with translational potential for noninvasive monitoring of ES patients.

Jonas Dohmen,Lucrezia De Santis,Bret M Stephens et al. Jonas Dohmen et al.

Standardized workflows and prompt processing are essential to ensure reliable mutation detection in clinical liquid biopsy applications.

Ding Jingnuo,Zhang Huachuan,Zhou Da et al. Ding Jingnuo et al.

Advances in liquid biopsy and molecular profiling are enabling real-time adaptation of therapy, moving GIST management toward a dynamic, personalized paradigm aimed at overcoming resistance and improving patient outcomes.

Jingjing Jiang,Liz Morrell,Malale Tungu et al. Jingjing Jiang et al.

Diagnosis by liquid biopsy has undergone validation in SSA. However, evidence on its economic value is needed, especially in limited-resource settings....We present a cost-utility analysis comparing liquid biopsy with conventional local histopathology for the diagnosis of paediatric BL in Tanzania....Results: Diagnosis by liquid biopsy results in a reduced burden of 9.4 DALYs per patient compared to 10.5 for histopathology (difference 1.11 DALYs, 95% confidence interval 0.13-2.06), and per-patient costs are $1978 higher (95% CI $1299-2840), due to greater diagnosis costs....Probabilistic sensitivity analysis indicates that liquid biopsy is more likely to be cost-effective than pathology, at any threshold above $1890/DALY averted....Conclusions: Diagnosis by liquid biopsy could be cost-effective when used to accelerate diagnosis of BL in children and young adults in Tanzania, depending on when it is implemented in the patient journey, model assumptions and the decision threshold chosen.

Jingyi Yang,Minpu Zhang,Chundi Gao et al. Jingyi Yang et al.

Leveraging next-generation technologies, we propose an integrated strategy: multimodal epigenetic therapies combined with real-time liquid biopsy profiling to shift from reactive management toward predictive prevention of resistance.

Maria Teresa De Angelis,Gianluca Santamaria,Angela Amaddeo et al. Maria Teresa De Angelis et al.

At the same time, liquid biopsy technologies and organoid platforms have transformed preclinical modelling and perioperative surveillance.

Chrysiida Florou-Chatzigiannidou,Eirini Papadopoulou,Vasiliki Metaxa-Mariatou et al. Chrysiida Florou-Chatzigiannidou et al.

Giulia Martini,Stefania Napolitano,Davide Ciardiello et al. Giulia Martini et al.

Colorectal cancer (CRC) is a heterogeneous malignancy, with various alterations in molecular signalling pathways driving disease progression and resistance to therapy. Liquid biopsy, as a source of circulating tumour DNA (ctDNA), has been u...

Blair V Landon,Jinny Huang,Ellie G Evangelopoulou et al. Blair V Landon et al.

Liquid biopsies are emerging as promising approaches to capture minimal residual disease (MRD) and interpret the heterogeneity of pathological responses after neoadjuvant therapy for patients with early stage cancers. Minimally invasive ana...

Abdullah Farasani Abdullah Farasani

Consequently, the interpretation of liquid biopsy signals requires a specific approach. The literature search was conducted in the PubMed and Scopus databases from 2010 to 2025.